Clinical Trials
14 trialsNCT06410534 2025-09-11
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT05456165 2024-12-31
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
Gritstone bio, Inc.
Phase 2 Withdrawn
NCT05284214 2023-09-15
SALIENT
Partner Therapeutics, Inc.
Phase 2 Withdrawn
NCT05504642 2023-04-18
CERAD-IMMUNE
Universitätsklinikum Köln
Phase 2 Withdrawn
NCT04607200 2022-01-11
AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Agenus Inc.
Phase 2 Withdrawn
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03126461 2020-08-20
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03767439 2019-12-18
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Columbia University
Phase 2 Withdrawn
NCT01913691 2019-12-17
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03149159 2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
Phase 2 Withdrawn
NCT01530984 2015-10-05
Ipilimumab and GMCSF Immunotherapy for Prostate Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT00357461 2013-05-15
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Withdrawn